{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:33:07Z","timestamp":1795026787713,"version":"4.10.2"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"La Caixa Foundation","award":["LCF\/PR\/GN17\/10300004"],"award-info":[{"award-number":["LCF\/PR\/GN17\/10300004"]}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["TriBEKa-17-519007"],"award-info":[{"award-number":["TriBEKa-17-519007"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["2019-AARF-644568"],"award-info":[{"award-number":["2019-AARF-644568"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government","award":["2017-SGR-892"],"award-info":[{"award-number":["2017-SGR-892"]}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["RYC-2013-13054"],"award-info":[{"award-number":["RYC-2013-13054"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["RYC2018-026053-I"],"award-info":[{"award-number":["RYC2018-026053-I"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["FJC2018-038085-I"],"award-info":[{"award-number":["FJC2018-038085-I"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["FJCI-2017-33437"],"award-info":[{"award-number":["FJCI-2017-33437"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["IJC2018-037478-I"],"award-info":[{"award-number":["IJC2018-037478-I"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP II 17\/00029"],"award-info":[{"award-number":["CP II 17\/00029"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00155"],"award-info":[{"award-number":["PI19\/00155"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["752310"],"award-info":[{"award-number":["752310"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"swedish research council","award":["2018-02532"],"award-info":[{"award-number":["2018-02532"]}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["681712"],"award-info":[{"award-number":["681712"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["201809-2016862"],"award-info":[{"award-number":["201809-2016862"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","award":["RDAPB-201809-2016615"],"award-info":[{"award-number":["RDAPB-201809-2016615"]}],"id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Alzheimer Foundation","award":["AF-742881"],"award-info":[{"award-number":["AF-742881"]}]},{"DOI":"10.13039\/100013278","name":"JPND","doi-asserted-by":"crossref","award":["JPND2019-466-236"],"award-info":[{"award-number":["JPND2019-466-236"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Understanding the changes that occur in the transitional stage between absent and overt amyloid-\u03b2 (A\u03b2) pathology within the Alzheimer\u2019s <jats:italic>continuum<\/jats:italic> is crucial to develop therapeutic and preventive strategies. The objective of this study is to test whether cognitively unimpaired individuals with a low burden of A\u03b2 pathology have a distinct CSF, structural, and functional neuroimaging biomarker profile.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cross-sectional study of 318 middle-aged, cognitively unimpaired individuals from the ALFA+ cohort<jats:italic>.<\/jats:italic> We measured CSF A\u03b242\/40, phosphorylated tau (p-tau), total tau (t-tau), neurofilament light (NfL), neurogranin, sTREM2, YKL40, GFAP, IL6, S100B, and \u03b1-synuclein. Participants also underwent cognitive assessments, <jats:italic>APOE<\/jats:italic> genotyping, structural MRI, [<jats:sup>18<\/jats:sup>F]-FDG, and [<jats:sup>18<\/jats:sup>F]-flutemetamol PET.<\/jats:p>\n                <jats:p>To ensure the robustness of our results, we used three definitions of low burden of A\u03b2 pathology: (1) positive CSF A\u03b242\/40 and &lt; 30 Centiloids in A\u03b2 PET, (2) positive CSF A\u03b242\/40 and negative A\u03b2 PET visual read, and (3) 20\u201340 Centiloid range in A\u03b2 PET. We tested CSF and neuroimaging biomarker differences between the low burden group and the corresponding A\u03b2-negative group, adjusted by age and sex.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The prevalence and demographic characteristics of the low burden group differed between the three definitions. CSF p-tau and t-tau were increased in the low burden group compared to the A\u03b2-negative in all definitions. CSF neurogranin was increased in the low burden group definitions 1 and 3, while CSF NfL was only increased in the low burden group definition 1. None of the defined low burden groups showed signs of atrophy or glucose hypometabolism. Instead, we found slight increases in cortical thickness and metabolism in definition 2.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>There are biologically meaningful A\u03b2-downstream effects in individuals with a low burden of A\u03b2 pathology, while structural and functional changes are still subtle or absent. These findings support considering individuals with a low burden of A\u03b2 pathology for clinical trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02485730\">NCT02485730<\/jats:ext-link><\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-021-00863-y","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T11:02:49Z","timestamp":1627383769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cognitively unimpaired individuals with a low burden of A\u03b2 pathology have a distinct CSF biomarker profile"],"prefix":"10.1186","volume":"13","author":[{"given":"Marta","family":"Mil\u00e0-Alom\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Shekari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Salvad\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Domingo","family":"Gispert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eider M.","family":"Arenaza-Urquijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Operto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Falcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Vilor-Tejedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Grau-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Sala-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"S\u00e1nchez-Benavides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Maria","family":"Gonz\u00e1lez-de-Ech\u00e1varri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Minguillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Fauria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Ni\u00f1erola-Baiz\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Perissinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryline","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendlyn","family":"Kollmorgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Su\u00e1rez-Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the ALFA study","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"issue":"6","key":"863_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329. https:\/\/doi.org\/10.1016\/S1474-4422(14)70090-0.","journal-title":"Lancet Neurol"},{"issue":"3","key":"863_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003.","journal-title":"Alzheimers Dement"},{"key":"863_CR3","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A \/ T \/ N : An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016:1\u201310."},{"key":"863_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"863_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292\u2013323. https:\/\/doi.org\/10.1016\/j.jalz.2016.02.002.","journal-title":"Alzheimers Dement"},{"key":"863_CR6","doi-asserted-by":"publisher","first-page":"175628641988881","DOI":"10.1177\/1756286419888819","volume":"12","author":"M Mil\u00e0-Alom\u00e0","year":"2019","unstructured":"Mil\u00e0-Alom\u00e0 M, Su\u00e1rez-Calvet M, Molinuevo JL. Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer\u2019s disease. Ther Adv Neurol Disord. 2019;12:175628641988881.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"863_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jalz.2019.01.004","volume":"15","author":"I Bos","year":"2019","unstructured":"Bos I, Vos S, Verhey F, Scheltens P, Teunissen C, Engelborghs S, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer\u2019s disease spectrum. Alzheimers Dement. 2019;15(5):644\u201354. https:\/\/doi.org\/10.1016\/j.jalz.2019.01.004.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"863_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384. https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3.","journal-title":"Lancet Neurol"},{"key":"863_CR9","doi-asserted-by":"publisher","first-page":"226ra30","DOI":"10.1126\/scitranslmed.3007901","volume":"6","author":"AM Fagan","year":"2014","unstructured":"Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer\u2019s disease. Sci Transl Med. 2014;6:226ra30.","journal-title":"Sci Transl Med"},{"issue":"9","key":"863_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804. https:\/\/doi.org\/10.1056\/NEJMoa1202753.","journal-title":"N Engl J Med"},{"issue":"7","key":"863_CR11","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1093\/brain\/awv112","volume":"138","author":"S Villeneuve","year":"2015","unstructured":"Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138(7):2020\u201333. https:\/\/doi.org\/10.1093\/brain\/awv112.","journal-title":"Brain."},{"issue":"2","key":"863_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1212\/WNL.0000000000007747","volume":"93","author":"GN Bischof","year":"2019","unstructured":"Bischof GN, Jacobs HIL. Subthreshold amyloid and its biological and clinical meaning. Neurology. 2019;93(2):72\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000007747.","journal-title":"Neurology."},{"issue":"19","key":"863_CR13","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1523\/JNEUROSCI.0485-18.2018","volume":"38","author":"SL Leal","year":"2018","unstructured":"Leal SL, Lockhart SN, Maass A, Bell RK, Jagust WJ. Subthreshold amyloid predicts tau deposition in aging. J Neurosci. 2018;38(19):4482\u20139. https:\/\/doi.org\/10.1523\/JNEUROSCI.0485-18.2018.","journal-title":"J Neurosci"},{"issue":"17","key":"863_CR14","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1212\/WNL.0000000000005354","volume":"90","author":"SM Landau","year":"2018","unstructured":"Landau SM, Horng A, Jagust WJ. Memory decline accompanies subthreshold amyloid accumulation. Neurology. 2018;90(17):e1452\u201360. https:\/\/doi.org\/10.1212\/WNL.0000000000005354.","journal-title":"Neurology."},{"key":"863_CR15","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1212\/WNL.0000000000003425","volume":"87","author":"GN Bischof","year":"2016","unstructured":"Bischof GN, Rodrigue KM, Kennedy KM, Devous MD, Park DC. Amyloid deposition in younger adults is linked to episodic memory performance. Neurology. 2016;87:2562\u20136.","journal-title":"Neurology"},{"issue":"4","key":"863_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357\u201367. https:\/\/doi.org\/10.1016\/S1474-4422(13)70044-9.","journal-title":"Lancet Neurol"},{"issue":"10","key":"863_CR17","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","volume":"80","author":"CR Jack","year":"2013","unstructured":"Jack CR, Wiste HJ, Lesnick TG, Weigand SD, Knopman DS, Vemuri P, et al. Brain \u03b2-amyloid load approaches a plateau. Neurology. 2013;80(10):890\u20136. https:\/\/doi.org\/10.1212\/WNL.0b013e3182840bbe.","journal-title":"Neurology"},{"key":"863_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack","year":"2017","unstructured":"Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 2017;13:205\u201316.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"863_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","volume":"14","author":"CL Sutphen","year":"2018","unstructured":"Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, et al. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(7):869\u201379. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.012.","journal-title":"Alzheimers Dement"},{"key":"863_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.trci.2016.02.003","volume":"2","author":"JL Molinuevo","year":"2016","unstructured":"Molinuevo JL, Gramunt N, Gispert JD, Fauria K, Esteller M, Minguillon C, et al. The ALFA project: a research platform to identify early pathophysiological features of Alzheimer\u2019s disease. Alzheimers Dement. 2016;2:82\u201392.","journal-title":"Alzheimers Dement"},{"key":"863_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clinbiochem.2013.12.024","volume":"47","author":"CE Teunissen","year":"2014","unstructured":"Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B. Biobanking of CSF: international standardization to optimize biomarker development. Clin Biochem. 2014;47:288\u201392.","journal-title":"Clin Biochem"},{"issue":"10","key":"863_CR22","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/alz.12131","volume":"16","author":"M Mil\u00e0-Alom\u00e0","year":"2020","unstructured":"Mil\u00e0-Alom\u00e0 M, Salvad\u00f3 G, Gispert JD, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer\u2019s continuum. Alzheimers Dement. 2020;16(10):1358\u201371. https:\/\/doi.org\/10.1002\/alz.12131.","journal-title":"Alzheimers Dement"},{"key":"863_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.clinbiochem.2019.05.005","volume":"72","author":"V Lifke","year":"2019","unstructured":"Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M, et al. Elecsys\u00ae Total-Tau and Phospho-Tau (181P) CSF assays: analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clin Biochem. 2019;72:30\u20138.","journal-title":"Clin Biochem"},{"key":"863_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","volume":"12","author":"T Bittner","year":"2016","unstructured":"Bittner T, Zetterberg H, Teunissen CE, Ostlund RE, Militello M, Andreasson U, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of \u03b2-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement. 2016;12:517\u201326.","journal-title":"Alzheimers Dement"},{"key":"863_CR25","unstructured":"Agency EM. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vizamyl-epar-product-information_en.pdf"},{"key":"863_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1\u201315.e4.","journal-title":"Alzheimers Dement"},{"key":"863_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3 G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Su\u00e1rez-Calvet M, et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res Ther. 2019;11:27.","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"863_CR28","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.neurobiolaging.2009.07.002","volume":"32","author":"SM Landau","year":"2011","unstructured":"Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32(7):1207\u201318. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2009.07.002.","journal-title":"Neurobiol Aging"},{"key":"863_CR29","doi-asserted-by":"crossref","unstructured":"Fischl B. FreeSurfer. Neuroimage. 2012:774\u201381.","DOI":"10.1016\/j.neuroimage.2012.01.021"},{"issue":"6","key":"863_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(17)30077-7","volume":"16","author":"CR Jack","year":"2017","unstructured":"Jack CR, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, et al. Age-specific and sex-specific prevalence of cerebral \u03b2-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50\u201395 years: a cross-sectional study. Lancet Neurol. 2017;16(6):435\u201344. https:\/\/doi.org\/10.1016\/S1474-4422(17)30077-7.","journal-title":"Lancet Neurol"},{"issue":"6","key":"863_CR31","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ana.23908","volume":"74","author":"SM Landau","year":"2013","unstructured":"Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid. Ann Neurol. 2013;74(6):826\u201336. https:\/\/doi.org\/10.1002\/ana.23908.","journal-title":"Ann Neurol"},{"key":"863_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.biopsych.2011.02.017","volume":"70","author":"J Fortea","year":"2011","unstructured":"Fortea J, Sala-Llonch R, Bartr\u00e9s-Faz D, Llad\u00f3 A, Sol\u00e9-Padull\u00e9s C, Bosch B, et al. Cognitively preserved subjects with transitional cerebrospinal fluid \u00df-amyloid 1-42 values have thicker cortex in Alzheimer\u2019s disease vulnerable areas. Biol Psychiatry. 2011;70:183\u201390.","journal-title":"Biol Psychiatry"},{"key":"863_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [11 C]PIB-PET Centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 2019;15:205\u201316.","journal-title":"Alzheimers Dement"},{"key":"863_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13195-020-00587-5","volume":"12","author":"S Amadoru","year":"2020","unstructured":"Amadoru S, Dor\u00e9 V, McLean CA, Hinton F, Shepherd CE, Halliday GM, et al. Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer\u2019s disease. Alzheimers Res Ther. 2020;12:22.","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"863_CR35","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1093\/brain\/aww160","volume":"139","author":"A Leuzy","year":"2016","unstructured":"Leuzy A, Chiotis K, Hasselbalch SG, Rinne JO, de Mendon\u00e7a A, Otto M, et al. Pittsburgh compound B imaging and cerebrospinal fluid amyloid-\u03b2 in a multicentre European memory clinic study. Brain. 2016;139(9):2540\u201353. https:\/\/doi.org\/10.1093\/brain\/aww160.","journal-title":"Brain."},{"key":"863_CR36","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","volume":"44","author":"CC Rowe","year":"2017","unstructured":"Rowe CC, Dor\u00e9 V, Jones G, Baxendale D, Mulligan RS, Bullich S, et al. 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. 2017;44:2053\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"863_CR37","unstructured":"AHEAD 3-45 study: a study to evaluate efficacy and safety of treatment with BAN2401 in participants with preclinical Alzheimer\u2019s disease and elevated amyloid and also in participants with early preclinical Alzheimer\u2019s disease and intermediate amyloid - Fu [Internet]. [cited 2020 Oct 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04468659?term=NCT04468659&draw=2&rank=1"},{"key":"863_CR38","doi-asserted-by":"crossref","unstructured":"Benjamini, Yoav ; Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289\u2013300.","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"issue":"4","key":"863_CR39","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist S, Mattsson N, Hansson O. Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography. Brain. 2016;139(4):1226\u201336. https:\/\/doi.org\/10.1093\/brain\/aww015.","journal-title":"Brain."},{"issue":"3","key":"863_CR40","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer\u2019s disease. Brain. 2015;138(3):772\u201383. https:\/\/doi.org\/10.1093\/brain\/awu367.","journal-title":"Brain."},{"issue":"1","key":"863_CR41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.14283\/jpad.2020.51","volume":"8","author":"M Mil\u00e0-Alom\u00e0","year":"2021","unstructured":"Mil\u00e0-Alom\u00e0 M, Salvad\u00f3 G, Shekari M, Grau-Rivera O, Sala-Vila A, S\u00e1nchez-Benavides G, et al. Comparative analysis of different definitions of Amyloid-B positivity to detect early downstream pathophysiological alterations in preclinical Alzheimer. J Prev Alzheimer\u2019s Dis. 2021;8(1):68\u201377. https:\/\/doi.org\/10.14283\/jpad.2020.51.","journal-title":"J Prev Alzheimer\u2019s Dis"},{"issue":"4","key":"863_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.exger.2012.01.008","volume":"47","author":"CPC Chen","year":"2012","unstructured":"Chen CPC, Chen RL, Preston JE. The influence of ageing in the cerebrospinal fluid concentrations of proteins that are derived from the choroid plexus, brain, and plasma. Exp Gerontol. 2012;47(4):323\u20138. https:\/\/doi.org\/10.1016\/j.exger.2012.01.008.","journal-title":"Exp Gerontol"},{"key":"863_CR43","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.neurobiolaging.2004.07.013","volume":"26","author":"C Masseguin","year":"2005","unstructured":"Masseguin C, LePanse S, Corman B, Verbavatz JM, Gabrion J. Aging affects choroidal proteins involved in CSF production in Sprague-Dawley rats. Neurobiol Aging. 2005;26:917\u201327.","journal-title":"Neurobiol Aging"},{"key":"863_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2045-8118-9-3","volume":"9","author":"C Chiu","year":"2012","unstructured":"Chiu C, Miller MC, Caralopoulos IN, Worden MS, Brinker T, Gordon ZN, et al. Temporal course of cerebrospinal fluid dynamics and amyloid accumulation in the aging rat brain from three to thirty months. Fluids Barriers CNS. 2012;9:3.","journal-title":"Fluids Barriers CNS"},{"issue":"3","key":"863_CR45","doi-asserted-by":"publisher","first-page":"E256","DOI":"10.1212\/WNL.0000000000009874","volume":"95","author":"AC Van Harten","year":"2020","unstructured":"Van Harten AC, Wiste HJ, Weigand SD, Mielke MM, Kremers WK, Eichenlaub U, et al. CSF biomarkers in Olmsted County: evidence of 2 subclasses and associations with demographics. Neurology. 2020;95(3):E256\u201367. https:\/\/doi.org\/10.1212\/WNL.0000000000009874.","journal-title":"Neurology."},{"key":"863_CR46","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1093\/brain\/awv199","volume":"138","author":"JB Toledo","year":"2015","unstructured":"Toledo JB, Zetterberg H, Van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, et al. Alzheimer\u2019s disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain. 2015;138:2701\u201315.","journal-title":"Brain"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00863-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00863-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00863-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T11:13:24Z","timestamp":1627384404000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00863-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00863-y","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ALFA+ study (ALFA-FPM-0311) was approved by the Independent Ethics Committee \u201cParc de Salut Mar\u201d, Barcelona, and registered at  (Identifier: NCT02485730). All participating subjects signed the study\u2019s informed consent form that had also been approved by the Independent Ethics Committee \u201cParc de Salut Mar\u201d, Barcelona.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approvals and consent to participate"}},{"value":"NA","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MS is a full-time employee of the Roche Diagnostics International Ltd. GK is a full-time employee of the Roche Diagnostics GmbH. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen; and is a co-founder of the Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD\/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers and is a co-founder of the Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. MSC has served as a consultant and at advisory boards for the Roche Diagnostics International Ltd. and has given lectures in symposia sponsored by the Roche Diagnostics, S.L.U, and Roche Farma, S.A. JLM is currently a full-time employee of H. Lundbeck A\/S and priory has served as a consultant or at advisory boards for the following for-profit companies, or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, and ProMIS Neurosciences. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}